Lisocabtagene maraleucel has been granted FDA approval for the treatment of patients with relapsed/refractory follicular lymphoma. Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, ...

Novartis' CAR-T Kymriah has become the first therapy in the category to be approved for the treatment of relapsed/refractory follicular lymphoma, ahead of Gilead Sciences' rival Yescarta.

Monjuvi, Revlimid and Rituxan improved progression-free survival among adults with relapsed or refractory follicular lymphoma, topline research showed.

Follicular lymphoma is a diverse disease, both biologically and clinically. Patients may present with indolent, asymptomatic disease or more aggressive, symptomatic disease with high tumor burden.

Incyte’s previously disclosed phase 3 win in relapsed or refractory follicular lymphoma (R/R FL) sent the company racing to file an expansion bid for its Monjuvi (tafasitamab) by year-end.

The index helps doctors figure out whether these treatments are needed. Follicular Lymphoma International Prognostic Index The IPI is useful for most lymphomas, but it’s not as helpful for follicular ...

Although many effective therapies are available for follicular lymphoma (FL), this lymphoma remains incurable with a continuous pattern of relapse and shorter duration of responses with subsequent ...

Check your free credit score and credit report as often as you want, and get alerts about changes so you can manage your credit effectively. Credit education Stay on top of your score with ...

Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy nivolumab to a current treatment regimen.